Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

Development of one paediatric and one neonatal formulary list in hospital settings

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Obesity-induced CYP2E1 activity in children

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Higher chlorzoxazone clearance in obese children compared with nonobese peers

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clarithromycin, trimethoprim, and penicillin and oxidative nucleic acid modifications in humans: randomised, controlled trials

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Authors' Reply to Santos et al.: "Excipients in Neonatal Medicinal Products: Never Prescribed, Commonly Administered"

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Discontinuation of diabetes medication in the 10 years before death: a nationwide register-based study: 21-25 September 2020.

    Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

  3. Shift From Adalimumab Originator to Biosimilars in Denmark

    Research output: Contribution to journalLetterpeer-review

  4. Midazolam Pharmacokinetics in Obese and Non-obese Children and Adolescents

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIMS: The aim of this study is to describe the stepwise process towards creating two formulary lists: one for paediatric and one for neonatal patients covering common diseases in hospital settings.

METHODS: This study presents the concept for developing a formulary list, namely how to: (1) organize the editorial board, (2) procure drug consumption data and database management, including information on labelling status, dosing options, excipients and problematic adverse events, current guidelines, evidence and price, (3) develop the first edition for the formulary list and formulary manual, and (4) to establish a paediatric sub-committee within the Regional Drug and Therapeutic Committee to maintain and continually develop the two formularies.

RESULTS: The total number of drugs was 411 ATC level 5, which covers 1097 unique item numbers prior to the paediatric formulary list, of which 263 item numbers were included in the final list. In neonates, 201 drugs ATC level 5 were evaluated, covering 348 unique item numbers, of which 104 item numbers were included in the final neonatal formulary list. Eighty-eight percent of the included drugs in the paediatric formulary were licensed to children (not specified by age group), 2% were unlicensed in Denmark, and 7% were extemporaneous preparations. For neonates, the percentage was 48%, 4% and 16%, correspondingly.

CONCLUSION: The process is time-consuming as studies are lacking and age-appropriate dosage forms and concentrations differ amongst countries. Nevertheless, the process should be somewhat similar between countries, albeit different drugs may be selected for the final formulary lists.

Original languageEnglish
JournalBritish Journal of Clinical Pharmacology
Volume84
Issue number2
Pages (from-to)349-357
ISSN0306-5251
DOIs
Publication statusPublished - 2018

    Research areas

  • Journal Article

ID: 52064740